5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
3 citations
,
January 2011 in “Annals of Dermatology” Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
45 citations
,
January 1992 in “Dermatology” Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.
EGFR helps protect hair follicles from damage and scarring.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
1 citations
,
June 2023 in “Advances in therapy” Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
81 citations
,
January 2003 in “The FASEB Journal” Follistatin helps hair growth and cycling, while activin prevents it.
2 citations
,
April 2017 in “Actas Dermo-Sifiliográficas” Best treatment for Frontal Fibrosing Alopecia is 5-alpha-reductase inhibitors and intralesional corticosteroids.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
58 citations
,
March 2020 in “Scientific Reports” EGFR-TKIs can cause significant skin, nail, and organ side effects.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
4 citations
,
April 2019 in “DOAJ (DOAJ: Directory of Open Access Journals)” 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine are the most effective treatments for frontal fibrosing alopecia.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
163 citations
,
October 2001 in “EMBO journal” Overexpressing follistatin in mice delays wound healing and reduces scar size.
29 citations
,
January 2016 in “CNS drugs” Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
February 2023 in “Acta Scientific Women s Health” New treatments like PBMC, G-CSF, and PRP show promise for helping with repeated implantation failure.
May 2024 in “Journal of Cosmetic and Laser Therapy” Injectable platelet-rich fibrin improves hair growth and reduces hair loss in women.
November 2023 in “Deleted Journal” Combining laser and corticosteroid is not better than corticosteroid alone for treating frontal fibrosing alopecia.
8 citations
,
January 2017 in “Stem Cells International” A protein called sFRP4 from skin cells stops the development of pigment-producing cells in hair.
3 citations
,
April 2016 in “Journal of Investigative Dermatology” Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
1 citations
,
July 2024 in “British Journal of Dermatology” Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.
1 citations
,
March 2016 in “Journal of The American Academy of Dermatology” More research needed to confirm finasteride as standard treatment for FFA.
30 citations
,
March 2011 in “Australasian Journal of Dermatology” Flutamide improves female hair loss when other treatments fail, but may cause liver toxicity.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
September 2022 in “XXXIX Congresso Brasileiro de Reumatologia” Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.